- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06609239
Долгосрочная оценка безопасности и эффективности лунсекимига (SAR443765) у взрослых участников с умеренной и тяжелой астмой. (AIRPHRODITE)
Открытое расширенное исследование для оценки долгосрочной безопасности и эффективности подкожного лунсекимига у взрослых участников с астмой средней и тяжелой степени, принявших участие в исследовании DRI16762
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.
The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.
Обзор исследования
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Buenos Aires, Аргентина, 1121
- Investigational Site Number : 0320005
-
Buenos Aires, Аргентина, 1414
- Investigational Site Number : 0320004
-
Buenos Aires, Аргентина, 1425
- Investigational Site Number : 0320001
-
Buenos Aires, Аргентина, 1122
- Investigational Site Number : 0320012
-
Buenos Aires, Аргентина, 1425
- Investigational Site Number : 0320011
-
La Plata, Buenos Aires, Аргентина, B1904CUL
- Investigational Site Number : 0320003
-
Mendoza, Аргентина, 5500
- Investigational Site Number : 0320009
-
Mendoza, Аргентина, 5500
- Investigational Site Number : 0320015
-
Santa Fe, Аргентина, 3000
- Investigational Site Number : 0320010
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Аргентина, 1886
- Investigational Site Number : 0320007
-
Lobos, Buenos Aires, Аргентина, 7240
- Investigational Site Number : 0320013
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, 2000
- Investigational Site Number : 0320002
-
Rosario, Santa Fe Province, Аргентина, 2000
- Investigational Site Number : 0320006
-
Rosario, Santa Fe Province, Аргентина, 2000
- Investigational Site Number : 0320020
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Аргентина, 4000
- Investigational Site Number : 0320008
-
-
-
-
-
Rio de Janeiro, Бразилия, 22241-180
- CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
-
São Paulo, Бразилия, 05403-000
- Incor - Instituto do Coracao- Site Number : 0760011
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Бразилия, 40060-330
- Associacao Proar- Site Number : 0760003
-
-
Goiás
-
Goiânia, Goiás, Бразилия, 74605-020
- Universidade Federal de Goias- Site Number : 0760007
-
-
Paraná
-
Curitiba, Paraná, Бразилия, 80030-110
- CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
-
-
Pernambuco
-
Recife, Pernambuco, Бразилия, 50070-550
- Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Бразилия, 89030-101
- Hospital Dia do Pulmão- Site Number : 0760005
-
-
-
-
-
Mosonmagyaróvár, Венгрия, 9200
- Investigational Site Number : 3480004
-
-
-
-
-
Leipzig, Германия, 04347
- Investigational Site Number : 2760001
-
Mainz, Германия, 55128
- Investigational Site Number : 2760005
-
-
-
-
-
Ashkelon, Израиль, 7830604
- Investigational Site Number : 3760006
-
Haifa, Израиль, 3104802
- Investigational Site Number : 3760001
-
Haifa, Израиль, 3436212
- Investigational Site Number : 3760008
-
Jerusalem, Израиль, 9103102
- Investigational Site Number : 3760003
-
Jerusalem, Израиль, 9112001
- Investigational Site Number : 3760002
-
Petah Tikva, Израиль, 4941492
- Investigational Site Number : 3760010
-
Rehovot, Израиль, 7610001
- Investigational Site Number : 3760004
-
Tel Aviv, Израиль, 6423906
- Investigational Site Number : 3760007
-
-
-
-
-
Calicut, Индия, 673008
- Investigational Site Number : 3560007
-
Hyderabad, Индия, 500084
- Investigational Site Number : 3560009
-
Kanpur, Индия, 208001
- Investigational Site Number : 3560008
-
Nagpur, Индия, 441203
- Investigational Site Number : 3560001
-
Pune, Индия, 411057
- Investigational Site Number : 3560004
-
-
-
-
-
Madrid, Испания, 28007
- Investigational Site Number : 7240008
-
Madrid, Испания, 28010
- Investigational Site Number : 7240011
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Испания, 08017
- Investigational Site Number : 7240009
-
-
-
-
Roma
-
Rome, Roma, Италия, 00168
- Investigational Site Number : 3800010
-
-
-
-
Ontario
-
Ajax, Ontario, Канада, L1S 2J5
- Investigational Site Number : 1240013
-
Hamilton, Ontario, Канада, L8N 4A6
- Investigational Site Number : 1240003
-
-
Quebec
-
Sherbrooke, Quebec, Канада, J1H 5N4
- Investigational Site Number : 1240004
-
Trois-Rivières, Quebec, Канада, G8T 7A1
- Investigational Site Number : 1240001
-
-
-
-
-
Beijing, Китай, 100144
- Investigational Site Number : 1560011
-
Changchun, Китай, 130021
- Investigational Site Number : 1560010
-
Changsha, Китай, 410015
- Investigational Site Number : 1560017
-
Chengde, Китай, 067020
- Investigational Site Number : 1560021
-
Guangzhou, Китай, 510150
- Investigational Site Number : 1560009
-
Guangzhou, Китай, 510000
- Investigational Site Number : 1560053
-
Guangzhou, Китай, 510163
- Investigational Site Number : 1560001
-
Guiyang, Китай, 550002
- Investigational Site Number : 1560037
-
Hefei, Китай, 230032
- Investigational Site Number : 1560006
-
Hohhot, Китай, 010050
- Investigational Site Number : 1560014
-
Lanzhou, Китай, 730000
- Investigational Site Number : 1560030
-
Nanchang, Китай, 330006
- Investigational Site Number : 1560007
-
Pingxiang, Китай, 337055
- Investigational Site Number : 1560002
-
Shanghai, Китай, 200433
- Investigational Site Number : 1560013
-
Shenyang, Китай, 110004
- Investigational Site Number : 1560015
-
Taiyuan, Китай, 030001
- Investigational Site Number : 1560057
-
Tianjin, Китай, 300211
- Investigational Site Number : 1560055
-
Wenzhou, Китай, 325027
- Investigational Site Number : 1560005
-
Wuhan, Китай, 430030
- Investigational Site Number : 1560003
-
Wuhan, Китай, 430030
- Investigational Site Number : 1560022
-
Xuzhou, Китай, 221006
- Investigational Site Number : 1560004
-
Yangzhou, Китай, 225000
- Investigational Site Number : 1560016
-
Zhanjiang, Китай, 524004
- Investigational Site Number : 1560012
-
-
-
-
-
Chihuahua City, Мексика, 31000
- Investigational Site Number : 4840002
-
Durango, Мексика, 34000
- Investigational Site Number : 4840003
-
Veracruz, Мексика, 91900
- Investigational Site Number : 4840008
-
-
Nuevo León
-
Monterrey, Nuevo León, Мексика, 66465
- Investigational Site Number : 4840004
-
-
Querétaro
-
San Juan del Río, Querétaro, Мексика, 76800
- Investigational Site Number : 4840005
-
-
Yucatán
-
Mérida, Yucatán, Мексика, 97070
- Investigational Site Number : 4840007
-
-
-
-
-
Chęciny, Польша, 26-060
- Investigational Site Number : 6160004
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Польша, 60-693
- Investigational Site Number : 6160001
-
-
-
-
-
Bradford, Соединенное Королевство, BD9 6DA
- Investigational Site Number : 8260008
-
Chertsey, Соединенное Королевство
- Investigational Site Number : 8260005
-
London, Соединенное Королевство, W1G 8HU
- Investigational Site Number : 8260011
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Соединенное Королевство, CB2 2QQ
- Investigational Site Number : 8260001
-
-
Glasgow City
-
Glasgow, Glasgow City, Соединенное Королевство, G12 0YN
- Investigational Site Number : 8260004
-
-
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85224
- Chandler Clinical Research Trials- Site Number : 8400075
-
Tucson, Arizona, Соединенные Штаты, 85712
- Tucson Clinical Research Institute- Site Number : 8400085
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80014
- Allianz Research Institute - Aurora- Site Number : 8400026
-
Wheat Ridge, Colorado, Соединенные Штаты, 80033
- Western States Clinical Research- Site Number : 8400014
-
-
Florida
-
Boynton Beach, Florida, Соединенные Штаты, 33435
- Helix Biomedics- Site Number : 8400114
-
Cutler Bay, Florida, Соединенные Штаты, 33157
- Beautiful Minds Clinical Research Center- Site Number : 8400049
-
Hialeah, Florida, Соединенные Штаты, 33010
- Qway Research - Hialeah- Site Number : 8400015
-
Miami, Florida, Соединенные Штаты, 33184
- High Quality Research- Site Number : 8400039
-
Miami, Florida, Соединенные Штаты, 33186
- Innovations Biotech- Site Number : 8400040
-
Miami, Florida, Соединенные Штаты, 33186
- New Access Medical Center- Site Number : 8400043
-
Miami, Florida, Соединенные Штаты, 33135
- Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
-
Miami Lakes, Florida, Соединенные Штаты, 33014
- Deluxe Health Center- Site Number : 8400045
-
Pembroke Pines, Florida, Соединенные Штаты, 33025
- Tellabio International Research Services- Site Number : 8400083
-
Pembroke Pines, Florida, Соединенные Штаты, 33029
- Alfa Medical Research LLC- Site Number : 8400146
-
Pensacola, Florida, Соединенные Штаты, 32503
- Avanza Medical Research Center- Site Number : 8400135
-
Saint Cloud, Florida, Соединенные Штаты, 34769
- Ilumina Medical Research- Site Number : 8400095
-
Sarasota, Florida, Соединенные Штаты, 34239
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
-
-
Georgia
-
Cordele, Georgia, Соединенные Штаты, 31015
- Private Practice - Dr. David Kavtaradze- Site Number : 8400081
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Brigham & Women's Hospital- Site Number : 8400034
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63141
- Midwest Clinical Research Center - St. Louis- Site Number : 8400006
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28287
- Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
-
-
Ohio
-
Toledo, Ohio, Соединенные Штаты, 43617
- Asthma & Allergy Center - Toledo- Site Number : 8400017
-
-
Oklahoma
-
Edmond, Oklahoma, Соединенные Штаты, 73034
- OK Clinical Research- Site Number : 8400021
-
-
Pennsylvania
-
DuBois, Pennsylvania, Соединенные Штаты, 15801
- Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15241
- Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78759
- Orion Clinical Research- Site Number : 8400001
-
Boerne, Texas, Соединенные Штаты, 78006
- South Texas Medical Research Institute - TTS Research- Site Number : 8400010
-
Dallas, Texas, Соединенные Штаты, 75246
- Baylor University Medical Center- Site Number : 8400002
-
El Paso, Texas, Соединенные Штаты, 79903
- Western Sky Medical Research- Site Number : 8400023
-
McKinney, Texas, Соединенные Штаты, 75069
- Metroplex Pulmonary and Sleep Center- Site Number : 8400022
-
-
-
-
-
Taipei, Тайвань, 110
- Investigational Site Number : 1580003
-
-
-
-
-
Bursa, Турция (Туркие), 16059
- Investigational Site Number : 7920006
-
Istanbul, Турция (Туркие), 34098
- Investigational Site Number : 7920002
-
Istanbul, Турция (Туркие), 34854
- Investigational Site Number : 7920003
-
Kayseri, Турция (Туркие), 38039
- Investigational Site Number : 7920007
-
Kirikkale, Турция (Туркие), 71100
- Investigational Site Number : 7920008
-
Mersin, Турция (Туркие), 33070
- Investigational Site Number : 7920001
-
İzmit, Турция (Туркие), 41001
- Investigational Site Number : 7920005
-
-
-
-
Biobio
-
Concepción, Biobio, Чили, 4070094
- Investigational Site Number : 1520013
-
-
Maule Region
-
Talca, Maule Region, Чили, 3465584
- Investigational Site Number : 1520001
-
-
Reg Metropolitana de Santiago
-
Recoleta, Reg Metropolitana de Santiago, Чили, 8420000
- Investigational Site Number : 1520015
-
Santiago, Reg Metropolitana de Santiago, Чили, 7500587
- Investigational Site Number : 1520006
-
Santiago, Reg Metropolitana de Santiago, Чили, 7500692
- Investigational Site Number : 1520005
-
Santiago, Reg Metropolitana de Santiago, Чили, 7500698
- Investigational Site Number : 1520004
-
Santiago, Reg Metropolitana de Santiago, Чили, 7750495
- Investigational Site Number : 1520002
-
-
Valparaiso
-
Quillota, Valparaiso, Чили, 2260877
- Investigational Site Number : 1520008
-
Viña del Mar, Valparaiso, Чили, 2531172
- Investigational Site Number : 1520011
-
Viña del Mar, Valparaiso, Чили, 2540364
- Investigational Site Number : 1520012
-
-
-
-
-
Benoni, Южная Африка, 1500
- Investigational Site Number : 7100004
-
Benoni, Южная Африка, 1500
- Investigational Site Number : 7100005
-
Cape Town, Южная Африка, 7530
- Investigational Site Number : 7100003
-
Cape Town, Южная Африка, 7700
- Investigational Site Number : 7100002
-
Durban, Южная Африка, 4001
- Investigational Site Number : 7100001
-
Pretoria, Южная Африка, 0157
- Investigational Site Number : 7100006
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Южная Корея, 03722
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Южная Корея, 03080
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Южная Корея, 05030
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Южная Корея, 05505
- Investigational Site Number : 4100006
-
Seoul, Seoul-teukbyeolsi, Южная Корея, 06351
- Investigational Site Number : 4100005
-
-
-
-
-
Fukushima, Япония, 960-1295
- Investigational Site Number : 3920008
-
Kyoto, Япония, 610-0113
- Investigational Site Number : 3920006
-
Kyoto, Япония, 612-8555
- Investigational Site Number : 3920009
-
Miyazaki, Япония, 889-1692
- Investigational Site Number : 3920012
-
-
Kagawa-ken
-
Sakaidechō, Kagawa-ken, Япония, 762-8550
- Investigational Site Number : 3920002
-
-
Tokyo
-
Chūō, Tokyo, Япония, 104-0031
- Investigational Site Number : 3920011
-
-
Yamaguchi
-
Ube, Yamaguchi, Япония, 755-8505
- Investigational Site Number : 3920005
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol
-
Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:
- For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
- For Study ACT18301: LABA with or without LTRA
-
Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures
-
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
For female participants:
- incapable of becoming pregnant, or
- not pregnant or breast feeding
- no eggs donation or cryopreserving eggs
For male participants:
-- No sperm donation or cryopreserving sperm
- Capable of giving signed informed consent
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
- Participant who was diagnosed with a new pulmonary disease which may impair lung function
- Current smoker or active vaping of any products and/or marijuana smoking
- Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
- History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
- Participants who are receiving prohibited concomitant medications
- Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Lunsekimig
Participants will receive subcutaneous injection of lunsekimig according to established dosing interval |
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Временное ограничение: From study baseline to week 148
|
Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year. |
From study baseline to week 148
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Annualized rate of asthma exacerbation events
Временное ограничение: From study baseline to weeks 48, 96 and 144
|
From study baseline to weeks 48, 96 and 144
|
|
|
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Временное ограничение: From parent study baseline to weeks 48, 96 and 144
|
From parent study baseline to weeks 48, 96 and 144
|
|
|
Serum lunsekimig concentrations
Временное ограничение: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Временное ограничение: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Временное ограничение: From parent study baseline to weeks 48, 96 and 144
|
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control. |
From parent study baseline to weeks 48, 96 and 144
|
|
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Временное ограничение: From parent study baseline to weeks 48, 96 and 144
|
Defined as ACQ-5 responder analysis |
From parent study baseline to weeks 48, 96 and 144
|
|
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Временное ограничение: From parent study baseline to weeks 48, 96 and 144
|
The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life. |
From parent study baseline to weeks 48, 96 and 144
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- LTS17231
- 2025-522896-27 (Идентификатор реестра: CTIS)
- U1111-1303-3645 (Идентификатор реестра: ICTRP)
- 2025 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .